The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases
Children's National Hospital and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) have launched the Rare Disease Clinical Activity Protocols (Rare-CAP) program. This initiative aims to standardize diagnosis and care for patients with rare diseases, supported by a $3.85 million investment from Takeda over five years. Rare-CAP will utilize a protocol platform that engages patients and families, providing real-time updates. The partnership emphasizes Takeda's commitment to innovation in rare diseases, as these conditions often lack standardized care protocols.
- Takeda's $3.85 million investment supports the growth and sustainability of the Rare-CAP program over five years.
- The Rare-CAP program aims to standardize care for rare diseases, potentially improving diagnosis timelines for patients.
- None.
WASHINGTON and CAMBRIDGE, Mass., March 1, 2021 /PRNewswire/ -- Children's National Hospital and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.
Rare-CAP will be led by the Rare Disease Institute at the new Children's National Research & Innovation Campus that opened in February 2021 on the grounds of the former Walter Reed Army Medical Center. A
Rare diseases impact hundreds of millions of families around the world1. Currently, no overarching model exists for uniform standards of care and diagnosis. It can take years for patients to receive a correct diagnosis for rare diseases. Even then, care protocols are often hard to find, amplifying the pain and anguish that families already face in their challenging medical journeys.
"Just as Wikipedia revolutionized how we think of the encyclopedia, the Takeda commitment will help harness technology to revolutionize access to care standards for rare disease," said Marshall Summar, M.D., founding director of the Children's National Rare Disease Institute and chief of the Division of Genetics and Metabolism at the hospital. "We are extremely grateful for Takeda and their support of our work to unify rare disease research and real-world clinical experience in a way that's never been done before."
"With a rare disease typically affecting fewer than 1 in 200,000 people2, there are unfortunately few standardized care protocols in place once a diagnosis is confirmed," says Tom Koutsavlis, M.D., Takeda head of U.S. Medical Affairs. "We're pleased to be part of this important effort with Children's National to help patients get faster access to the optimized treatment for their particular rare disease diagnosis, which is critical in helping them achieve better health. In addition, this partnership underscores our commitment to driving continuous innovation and personalized care for patients with rare diseases."
The Children's National Rare Disease Institute is a first-of-its-kind center focused exclusively on advancing the care and treatment of children and adults with rare genetic diseases. It is the first NORD Designated Clinical Center of Excellence and provides a medical home for patients and families seeking the most advanced care and expertise for rare genetic conditions that remain largely unknown to the general medical community. Takeda's commitment represents one of the institute's founding partnerships.
Takeda aspires to transform the treatment of rare diseases in immunology, gastroenterology, neurology, oncology, hematology, metabolic and lysosomal storage disorders. These rare diseases can have symptoms that vary widely and progress very differently from person to person, which means that people affected by these diseases are frequently misdiagnosed.
About Children's National Hospital
Children's National Hospital, based in Washington, D.C., celebrates 150 years of pediatric care, research and commitment to community. Volunteers opened the hospital in 1870 with 12 beds for children displaced after the Civil War. Today, 150 years stronger, it is among the nation's top 10 children's hospitals. It is ranked No.1 for newborn care for the fourth straight year and ranked in all specialties evaluated by U.S. News & World Report. Children's National is transforming pediatric medicine for all children. In 2021, the Children's National Research & Innovation Campus will open, the first in the nation dedicated to pediatric research. Children's National has been designated three times in a row as a Magnet® hospital, demonstrating the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty care locations in the D.C. metropolitan area, including the Maryland and Northern Virginia suburbs. Children's National is home to the Children's National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation and is the nation's seventh-highest NIH-funded children's hospital. It is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels.
For more information, follow us on Facebook, Instagram, Twitter and LinkedIn.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries.
For more information, visit https://www.takeda.com.
1 World Health Organization, Priority diseases and reasons for inclusion, 6.19; https://www.who.int/medicines/areas/priority_medicines/Ch6_19Rare.pdf accessed 2/17/21
2 National Institutes of Health, Genetic and Rare Diseases Information Center: rarediseases.info.nih.bov/diseases, accessed 2/17/2021
View original content to download multimedia:http://www.prnewswire.com/news-releases/the-childrens-national-hospital-rare-disease-institute-and-takeda-partner-to-standardize-care-for-patients-with-rare-diseases-301237640.html
SOURCE Children's National Hospital
FAQ
What is the Rare-CAP program announced by Takeda and Children's National Hospital?
How much is Takeda investing in the Rare Disease Clinical Activity Protocols program?
When was the Rare-CAP program launched?
What is the significance of the partnership between Takeda and Children's National Hospital?
What does the Rare-CAP program aim to achieve for patients with rare diseases?
